Cargando…
To screen or not to screen: the prostate cancer dilemma
The European Randomized Study of Screening for Prostate (ERSPC) has updated their previous seminal report on prostate cancer mortality comparing screened men to controls. Now with 13 years follow-up, the rate ratio of prostate cancer mortality was 0.79 favoring the screened population. The authors c...
Autores principales: | Stone, Nelson N, Crawford, E David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4291875/ https://www.ncbi.nlm.nih.gov/pubmed/25337849 http://dx.doi.org/10.4103/1008-682X.142770 |
Ejemplares similares
-
Prostate cancer screening: and yet it moves!
por: Kwiatkowski, Maciej, et al.
Publicado: (2015) -
Appraising the European randomized study of screening for prostate cancer: what do the results mean?
por: Ilic, Dragan
Publicado: (2015) -
PSA screening – for whom and when?
por: Albers, Peter
Publicado: (2019) -
Lipogenic metabolism: a viable target for prostate cancer treatment?
por: Liang, Mengmeng, et al.
Publicado: (2014) -
HOXB13 and other high penetrant genes for prostate cancer
por: Pilie, Patrick G, et al.
Publicado: (2016)